Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing
Abstract Chimeric Antigen Receptor (CAR) T-cells represent a breakthrough in personalized cancer therapy. In this strategy, synthetic receptors comprised of antigen recognition, signaling, and costimulatory domains are used to reprogram T-cells to target tumor cells for destruction. Despite the succ...
Gorde:
| Egile Nagusiak: | , , |
|---|---|
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
BMC
2022-03-01
|
| Saila: | Molecular Cancer |
| Gaiak: | |
| Sarrera elektronikoa: | https://doi.org/10.1186/s12943-022-01559-z |
| Etiketak: |
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|